A B S T R A C T The role of particle-bound complement proteins in the induction of noncytotoxic enzyme release from human granulocytes was investigated with the use of sera genetically deficient in complement and highly purified complement components. Release of histaminase, one of two important histamine catabolizing enzymes, and B-glucuronidase from polymorphonuclear leukocytes was solely dependent on particlebound C3b (the larger cleavage product of the third component of complement) when fluid-phase complement was excluded. The extent of enzyme release was a function of particle-bound C3b input, was reduced by exposing the particles to C3b inactivator, and was blocked by fluid-phase C3b. Phagocytosis of the C3b-coated particles was not required for enzyme release from neutrophils.
In contrast, phagocytosis of "opsonized" particles was required for noncytotoxic release of histaminase and arylsulfatase from eosinophils; other proteins, as well as C3b, were able to opsonize particles for induction of enzyme release from eosinophils.
These studies suggest a dual role for complement (particularly C3) in modulating vascular permeability phenomena, i.e., release of vasoactive mediators by the action of C3a and C5a, and release ofthe corresponding enzymes that inactivate the mediators by C3b. INTRODUCTION The serum complement system was discovered in the late nineteenth century because of its cytolytic effect; i.e., ability to induce membrane damage (1, 2) . Since then, other important biologic activDr. Davis is the recipient of U. S. Public Health Service Fellowship AM5-F-32-AM05440. Dr. Zeiger's present address is 6273 Camino, San Diego, Calif. 92120. Received for publication 3 November 1978 and in revised form 26 December 1978. ities of complement have been recognized. These include immune adherence (3) , viral neutralization (4), chemotactic (5) and opsonic (6) functions, as well as histamine release from basophils and mast cells (7) .
Complement-dependent histamine release is mediated by anaphylatoxins, fragments ofthe third (C3) and fifth (C5) components of complement. These active polypeptides, C3a (9,000 daltons) (8) and C5a (11,000 daltons) (9) , are cleaved from the alpha chains ofC3 and C5, respectively. C5a, in addition, has been shown to mediate release of lysosomal enzymes from polymorphonuclear leukocytes, especially in the presence of cytochalasin B (10) . The larger fragments of C3 and C5 cleavage, C3b and C5b, participate in further activation of the complement sequence, but, in the case of C3b, also interact with specific cell surface binding sites to effect cellular events (11) .
We have previously shown that histaminase, one of two important histamine-catabolizing enzymes in humans, was released from eosinophils and neutrophils during incubation with zymosan opsonized with normal human serum; zymosan prepared with heated serum did not induce histaminase release (12, 13) . These experiments were performed under conditions that excluded the action of fluid-phase complement components (e.g., C3a, C5a). This observation suggested the possibility that surface-bound components of the serum complement system might be essential for the preparation of zymosan to effect histaminase release from human leukocytes.
The availability of sera from patients with genetic deficiencies of individual complement proteins and the purified components has made it possible to define the role of complement in opsonized zymosan-induced histaminase release from granulocytes. These studies indicated that noncytolytic enzyme release from polymorphonuclear leukocytes is a result of action of particle-bound C3b at the cell surface and does not require phagocytosis of C3b-coated particles to induce release. (17) .
Preparation of eosinophils. In some experiments, eosinophils were purified by a modification ofthe method described by Parrillo and Fauci (18) . Granulocyte suspensions were obtained, as described above, from patients with 15-60% eosinophils. The CB was used at 5 ,ug/ml, a concentration determined in previous experiments (12, 13) , to block phagocytosis of opsonized zymosan. In some experiments, parallel studies with high particle-to-cell ratios were performed to confirm the inhibition of phagocytosis by CB.
Viability of cells. Cell viability at the end of each experiment was assessed by either trypan blue exclusion or lactic dehydrogenase release (19) . Only experiments in which >90% of the cells remained viable by these criteria are reported.
Preparation of zymosan. Zymosan was opsonized by incubating 10 mg of boiled washed zymosan with 1 ml of fresh normal human serum for 30 min at 37°C, then washing (three times) in Tris A buffer to remove nonadherent serum components. Zymosan was also prepared in a similar manner with sera from patients homozygous for deficiencies of the second, third, fifth, and sixth components of complement (20) . The C5-and C6-deficient sera were generous gifts of Dr (22) were washed in Tris A, then suspended in Tris ACM, and used without further manipulation. C3b was purified from this patient's plasma by a method for C3 separation (21) . The C3b eluted in the later fractions of hydroxylapatite (Bio-Rad Laboratories, Richmond, Calif.). Electrophoretic mobility and immunochemical analysis ofthis purified material was consistent with its identification as C3b. Cobra-venom factor (CoF) was purified from Naja naja venom as described (23) . Erythrocyte complement intermediates, EAC1423, were prepared by the method of Rapp and Borsos (24) . Highly purified human C3b inactivator was prepared by Dr. F. S. Rosen, as described (25) . Human factor B was purified by the method of Boenisch and Alper (26) . C3, CoF, and factor B were radiolabeled with 125I by the iodine monochloride technique (27) .
Preparation of Sephadex C3b. Sephadex C3b was prepared according to the technique ofArnaout et al. (28) . Briefly, normal human serum was dialyzed overnight at 4°C against veronal-buffered saline (pH 7.35) with 10 mM EGTA and 5 mM Mg. Equal volumes of Sephadex G-75 and dialyzed normal human serum diluted 1:4 in veronal-buffered salineMg EGTA buffer were incubated at 37°C with gentle shaking. At timed intervals, portions were removed, washed with 150-fold vol ofa 2 M NaCl solution, the beads collected by vacuum on Whatman No. 1 filters (Whatman, Inc., Clifton, N. J.), then washed with 50-fold vol of phosphate-buffered saline, pH 7.2. The concentration of particles was adjusted to 1 x 107 beads/ml and used to induce enzyme release.
A small portion of each of the batches of washed Sephadex was resuspended in 4 vol of phosphate-buffered saline with 100 ,ul dextranase (1 mg/ml) (150 U/mg, Worthington Biochemical Corp., Freehold, N. J.) and shaken for 12 h at room temperature. The mixtures were then centrifuged at 1,500 rpm for 10 min, the supernatant fluid was concentrated 10-fold in collodion bags (Schleicher & Schuell, Inc., Keene, N. H.), then dialyzed against phosphate-buffered saline. The concentrates were analyzed on 1% sodium dodecyl sulfate (SDS)-7.5% polyacrylamide gels according to the method of Laemmli (29) .
Enzyme assays. Histaminase was determined by a radiochromatographic assay (15) on cellulose chromatogram plastic sheets (Eastman Kodak Co.) with butanol:concentrated acetic acid:water (4:1:1) as solvent. The area that contained histamine-degradation products was cut and its radioactivity measured by scintillation spectrometry.
The total intracellular histaminase content was measured in the fluid phase, obtained after incubating untreated cell suspensions with 2.5 ,ug/ml calcium ionophore or 0.1% Triton X-100 followed by ultrasonic disruption at 4°C (five, 5-s watt bursts separated by 1- (32) .
The total intracellular beta glucuronidase, arylsulfatase, and LDH was measured on the supematant solution obtained after incubating untreated cell suspensions in 0.1% Triton X-100 followed by ultrasonic disruption as described above for histaminase.
RESULTS
Zymosan prepared with complement-deficient sera: effect on leukocyte enzyme release. Histaminase and f3-glucuronidase release from normal neutrophils was induced by zymosan opsonized with normal human serum (Fig. 1) . Zymosan opsonized with serum from patients with homozygous deficiencies of C2, CS, or C6 were equally effective in triggering release of both enzymes from neutrophils. In contrast, zymosan pre- Similarly, histaminase and arylsulfatase were released from eosinophils by zymosan opsonized with normal human serum or with C2-, C5-, or C6-deficient serum, but not with C3-deficient serum. The addition of highly purified C3 or CoF to C3-deficient serum restored its ability to prepare zymosan for enzyme release from eosinophils. For neutrophils, the capacity to release histaminase by zymosan opsonized with C3-deficient serum was restored only with purified C3, but not by CoF (Fig. 1) .
Effect of C3 input on histaminase release. To quantitate the effect of C3 on zymosan-induced histaminase release, varying concentrations of radiolabeled C3 were mixed with C3-deficient serum and zymosan. The opsonized zymosan was washed and a portion removed for determination of C3 uptake, and other portions used to induce enzyme release. Leukocytes were incubated with varying concentrations of a single batch of prepared zymosan particles (0.24 gg C3/particle; 0.63-5.0 particles/cell) or with batches of zymosan prepared with varying concentrations of bound C3 (2.5 particles/cell; 0.06-0.5 Ag C3/particle). In each case, the extent of histaminase release from neutrophils was a function of C3 input (Fig. 2) . That is, the extent of enzyme release was independent of the number of particles on which the bound C3 (C3b) was release. Human erythrocytes in the form of EC3b from a patient with genetic deficiency of C3b-inactivator, induced release ofabout 50% ofneutrophil histaminase at a ratio of 20:1 erythrocytes:neutrophil. Decreasing numbers oferythrocytes/neutrophil lead to correspondingly less histaminase release. Release was markedly decreased by treating the erythrocytes with purified C3b-inactivator for 20 min at 37°C (Table II) .
Batches of Sephadex-C3b were washed at timned intervals after incubation of Sephadex G-75 with human serum, as described in Methodls. The beads were then incutbated with neutrophils for 30 mmin at 37°C and enzyme release measured. A portion of each Sephadex-C3b batch was assayed for C3 size anid structure on SDS-polyacrylamide gels and C3 protein quantitated by electroimmuniodiffusion. The results, shown in Fig. 3 Effect of fluid-phase C3b on zymosan-induced histaminase release. Neutrophils were pre-incubated with C3b for 20 min at 370C before addition of washed zymosan that had been opsonized with normal serum. At concentrations between 1.0 and 10 ug/ml, fluidphase C3b inhibited zymosan-induced release when the cells (5 x 106) were exposed to 0.5 ,ug bound C3b on 2.5 zymosan particles/cell (Fig. 4) . Fluid-phase C3b also inhibited histaminase release induced by 1 x 107 C3b-coated erythrocytes -50% at a concentration of fluid-phase C3b of 10 ,g/ml (Table III) . Fluid-phase C3b alone had no effect on enzyme release. Zymosan-induced enzyme release from eosinophils. Eosinophil-rich cell suspensions were incubated with zymosan previously prepared with C3-deficient serum and radiolabeled C3 (Fig. 5) (Fig. 6 ), but not neutrophils (Fig. 1) . (Fig. 6 ). DISCUSSION Several lines of evidence presented here indicate that release of histaminase and ,B-glucuronidase from human polymorphonuclear leukocytes can be induced by the action of particle-bound C3b at the cell surface. These include the findings that: (a) C3 on zymosan, erythrocytes, and Sephadex beads induced noncytotoxic enzyme release in a dose-dependent manner; (b) the extent of release was independent of the distribution of C3 protein on the particle (i.e., was solely dependent on the amount of C3 presented/neutrophil and not on the distribution of C3b on the particle); (c) enzyme release was induced even in the presence of CB at a concentration sufficient to block phagocytosis; (d) zymosan prepared with serum from patients genetically deficient in C3 (<0.01% normal C3 concentration) (33) failed to induce enzyme release (reconstitution of the serum required C3; CoF, a C3b analogue that is capable of activating the alternative complement pathway did not substitute for C3 for induction of enzyme release); (e) of the protein bound to Sephadex G-75 particles that induced release, >90% was in the form of C3b; (f) enzyme-releasing activity was removed from C3b-coated erythrocytes by the action of highly purified C3b inactivator; and (g) zymosan-and EC3b-induced release was inhibited by fluid-phase C3b. Relatively low concentrations of fluid-phase C3b were required, because it is probable that only a small portion ofthe particle-bound C3b is presented to the cells.
The calculated requirement of about 105 particlebound C3b molecules/neutrophil to effect 50% histaminase release must be considered maximum; a minimum estimate is not possible under these experimental conditions. Only a few hundred C3b molecules/ cell are required to generate the immune adherence phenomenon (34) or immune hemolysis (35) .
The capacity of C5a to induce 8-glucuronidase release is well-estal)lished (10), b)ut its effect on histaiminiiase release hadl not yet leen tested. However, in the presenit stu(lies, an ab)solute re(luiremiienit for particle-bound C51), the larger fratgmlenit (lerived from activationi of C5, was excludled 1v the findinig that release induced by zymiiosani preparedl in C5-deficient serum was indistiniguishable from normiial.
Results of an earlier study (12) suggested a (lualitative differeniee in mechaniismii of release of histamiiniiase from eosinophils and neutrophils. CB, at concenitrations that block phatgocytosis aind enhancee enizymile release from neutrophils, inhibited zvinosan-indlllcedl histamlniinase and arylsulfatase release fromii eosiniophils (12) . The observation that CoF, a C3b analogue, can sul)stitute for C3 itself in preparinig zymosan for induction of enzyme release from eosiniophils, l)ut not neutrophils, revealed another (ualitative (lifference betweeni the two cell types with respect to release mechanismiis, i.e., ani absolute dependenice on bound C3b in the neutrophil, but not for the eosinophil. There was n1o detectable uptake of CoF on the zymosan. It is probable that "opsonization" was accoimlplished by depositioIn on1 zymosan of a serum comiponienit other thani C3b that dependls on activationi of the alternative pathway. Support for the re(quiremenit of ani otherwise intact alternative pathway for enzyme release from eosinophils was obtained in an experimiienit, where depleting factor B in a C3-deficient seruIml blocked the ability of CoF to reconistitute the serumil. Addition of purified factor B back to the mixture generated ain activity on1 zymosan that promoted phagocytosis (data not shown) and noncvtotoxic enzyme release. These data are consistenit with those of Metcalf et al. (36) who showed a re(uirement for alterniative complement pathway activity for particle-bounid arylsulfatase release from human eosinophils. However, our findinigs indicate that in the absence of C3, deposition of other properdin pathway-depenident proteins can prepare a particle for induction of histaminase an(d arylsulfatase release from eosinophils.
The data presented here aind( elsewhere (31) suggest that local tissue conicentrations of allergic mediators, i.e., histamine and slow reacting substance of anaphylaxis may be regulated by complex-reciprocating control mechanisms. For example, cleavage of C3 to C3a and C3b would effect release of histacmine from mast cells (C3a) and histaminase from neutrophils or eosinophils (C3b). The rate of generation of C3 cleavage products, their rates of inactivation by anaphylatoxin inactivator and the C3b inactivator (11) (including ,81H), and the kinetics of histacminase and arylsulfatase activity may serve to modulate the biological effects of histamine and slow reacting substance of anaphylaxis.
